A 23-year-old graduate student comes into the clinic between his parents, who found him awake at 4 a.m. mapping the campus wifi network onto a bedsheet with a marker. Over the past eight months he has become certain that the network is broadcasting his thoughts to the people he passes on the quad. He hears a voice narrating what he does. He has stopped going to lab. The diagnosis almost writes itself: first-episode psychosis, most likely schizophrenia. What the diagnosis does not tell his parents, or the physician sitting across from them, is why his brain arrived at this point, or which of the several biological processes we now know can drive this illness are actually running in his particular case.
For most of a century the answer to that "why" was a single molecule. Too much dopamine in the wrong part of the brain. That story was never wrong, exactly. It was incomplete in a way that mattered, and the research of the last five years has rewritten it into something a physician can act on.
Dopamine Is the Last Step, Not the First
The classical dopamine hypothesis held that psychosis is a state of dopamine excess. Molecular imaging has sharpened that picture. What is elevated in schizophrenia is not dopamine flooding the whole brain but the striatum's capacity to synthesize it, and that elevation shows up in the prodromal phase, before the first psychotic break, and mostly in the people who go on to convert to full psychosis (McCutcheon, Reis Marques, and Howes, JAMA Psychiatry, 2020).
Dopamine neurons in these circuits normally tag the world with salience. They fire when something matters, when a reward is better or worse than expected. In schizophrenia that signal comes loose from reality. Dopamine gets released in response to things that carry no real meaning, and the brain, doing its job faithfully, concludes that those things must matter enormously. A stranger's glance, a license plate, a song on the radio: each gets stamped as personally meant. That is a mechanism for delusions and ideas of reference, not a metaphor for them.
The larger shift is that dopamine is now understood as the final common pathway, the last domino, rather than the root cause. Howes and Shatalina (Biological Psychiatry, 2022) tie the dopamine story to the older neurodevelopmental one through cortical excitation-inhibition balance. Early in development the brain over-prunes its synapses, including glutamate inputs onto the GABA interneurons that keep the frontal cortex in check. Lose that inhibition and two things follow: the cognitive and negative symptoms that come from a frontal cortex that cannot regulate itself, and a downstream disinhibition of the circuits that ride herd on those striatal dopamine neurons. The cortex loses control of the accelerator, and the striatum floors it. Genetics fits this frame cleanly, with risk variants clustering in genes for GABA, glutamate, neurodevelopment, and the D2 receptor itself.
The Immune System Was Left Out of the Story
Here is the part conventional psychiatry has been slowest to absorb. Schizophrenia is, in a large fraction of patients, a neuroinflammatory illness, and the inflammation is not a byproduct of being sick or being medicated. It comes first.
Interleukin-6 rises before psychosis onset. Mendelian randomization, which uses inherited genetic variation as a natural experiment to test causation rather than correlation, links genetically higher IL-6, its soluble receptor, and the soluble IL-2 receptor to increased schizophrenia risk (Upthegrove and colleagues, JAMA Psychiatry, 2025). The single strongest common genetic risk factor found so far is variation in the complement component 4 gene, part of the immune cascade that also happens to tag synapses for elimination.
The mechanism turns out to be stranger and more interesting than "the brain is inflamed." Recent transcriptomic and radioligand work suggests microglia in schizophrenia are not simply switched into a classic inflammatory attack mode. They are diverted into a synaptic-remodeling phenotype, pruning connections that should have been left alone (Corsi-Zuelli and Deakin, Neuroscience and Biobehavioral Reviews, 2021). The adaptive immune system is involved as well. The IL-6/IL-23/Th17 axis is turned up, most of all in deficit schizophrenia, the subtype dominated by negative symptoms, and regulatory T cell function is impaired, which loosens the brakes on exactly this kind of glial misbehavior. Denmark's population data close the loop: severe infections and autoimmune disorders are independent risk factors for later schizophrenia.
This is not an academic footnote. It means two patients with the same DSM diagnosis can have different engines running underneath, and that a blood draw can begin to tell them apart.
Why This Changes the Workup
A diagnosis of schizophrenia, as usually delivered, ends the investigation. From a precision-neurology standpoint it should begin one. This is the same argument I have made about why a serious brain workup needs six data streams, not one, and psychosis is where it bites hardest.
Inflammatory markers are the obvious starting point. A patient with an elevated CRP or IL-6 is telling you something about which biology is active, and there is a live research question, not yet settled, about whether those same patients are the ones who respond to anti-inflammatory add-on treatment. Nutritional status is the other underused lever. People with schizophrenia run low on omega-3 fatty acids, vitamin D, B6, folate, B12, zinc, and selenium at rates far above the general population (Aucoin and colleagues, Neuropsychobiology, 2020), and those deficits are not cosmetic. They feed directly into the oxidative and inflammatory machinery already described.
On the treatment side, the supplement with the most credible evidence is N-acetylcysteine. In a network meta-analysis of nutraceutical add-ons (Fornaro and colleagues, Molecular Psychiatry, 2025), NAC came out near the top, with a standardized mean difference around −0.87 for total symptoms and clear effects on negative symptoms, working through antioxidant, anti-inflammatory, and glutamate pathways at once. B-vitamin supplementation reduces overall symptoms, more so earlier in the illness (Firth and colleagues, Psychological Medicine, 2017). Sarcosine and citicoline also beat placebo. None of this replaces an antipsychotic, and I want that to be clear. It addresses the metabolic and immune terrain the antipsychotic ignores, which is exactly the terrain we build the Intensive Brain Health Program around, and it is why our clinic treats the nutritional biochemistry of a brain under stress as part of the medicine rather than an afterthought.
The First Antipsychotic in Decades That Ignores Dopamine
Every antipsychotic ever approved, from chlorpromazine in the 1950s to the newest atypicals, works by blocking the D2 dopamine receptor. That is why they share the same liabilities: movement disorders, weight gain, sedation, elevated prolactin. In September 2024 the FDA approved the first drug that breaks the pattern.
Xanomeline-trospium, sold as Cobenfy, does not touch the dopamine receptor at all. Xanomeline is an agonist at the M1 and M4 muscarinic acetylcholine receptors, and it lowers dopamine release in the associative striatum, the region that matters for psychosis, while sparing the sensorimotor striatum, the region whose disruption produces movement side effects. The trospium half is a muscarinic blocker engineered to stay outside the brain, mopping up the peripheral cholinergic effects that sank earlier attempts at this approach. Across three randomized trials, including EMERGENT-2 (Kaul and colleagues, The Lancet, 2024), it produced a pooled effect on total PANSS symptoms of about −0.56, with no extrapyramidal symptoms, no meaningful weight gain, no rise in prolactin, and a drop in LDL cholesterol. A 52-week open-label extension (American Journal of Psychiatry, 2026) held the improvement. The real costs are gastrointestinal, nausea and constipation, and some elevation in blood pressure.
Cobenfy is the first of several shots on a non-dopaminergic goal. Ulotaront, an agonist at the trace-amine receptor TAAR1, looked promising in phase 2 (Koblan and colleagues, New England Journal of Medicine, 2020) before mixed phase 3 results cooled expectations, and glycine-transporter inhibitors like iclepertin are still in the pipeline aimed at the glutamate side of the illness. The point is not that any one of these is a cure. It is that after seventy years of variations on a single mechanism, the field finally has more than one target.
The Horizon: Repairing the Circuit, Not Just Quieting It
Everything above manages symptoms or terrain. The most interesting preclinical work asks a different question: can you repair the damaged circuit itself? In rodent models, transplanting mesenchymal stem cells produced lasting improvement in schizophrenia-like behavior along with new hippocampal neurogenesis, and the benefit outlasted clozapine (Gobshtis and colleagues, Molecular Psychiatry, 2021). In another model, human umbilical-cord stem cells worked by inducing regulatory T cells and IL-10 to shut down neuroinflammation (You and colleagues, Translational Psychiatry, 2020), which connects the cellular therapy directly back to the immune model. Transplanted interneurons have integrated into the hippocampus and normalized the aberrant dopamine firing downstream.
These are animal studies. I mention them not because anyone should be marketing stem cells for psychosis today, because no one responsibly can, but because they show what the next decade of treatment is aiming at: the immune-neural interface that dopamine blockade never reaches.
What This Means for a Family in the Exam Room
If you are facing a first episode in someone you love, or a diagnosis that has not responded to two or three medications, the useful takeaway is that "schizophrenia" is a starting category, not a finished explanation. It is reasonable to ask whether inflammatory markers have been checked, whether nutritional deficiencies have been corrected, and whether a non-dopaminergic option like Cobenfy fits, especially when side effects have made the standard drugs intolerable. None of that is fringe. It is where the published science already sits.
The Neuroeconomy runs on cognition, and there is no clearer case of cognition under siege than a young brain pulled out of school or work by an illness we once treated as fixed and are now learning to treat as biology. Schizophrenia is brain failure of a specific, increasingly legible kind. Legible is treatable.